Rosiglitazone
- Generic Name
- Rosiglitazone
- Brand Names
- Avandamet, Avandia
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N3O3S
- CAS Number
- 122320-73-4
- Unique Ingredient Identifier
- 05V02F2KDG
- Background
Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellula...
- Indication
Rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 862
- Registration Number
- NCT00428090
- Locations
- 🇬🇧
GSK Investigational Site, West of Scotland Science Park, Glasgow, United Kingdom
Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2007-01-26
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 227
- Registration Number
- NCT00427154
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Tacoma, Washington, United States
Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride
- First Posted Date
- 2007-01-22
- Last Posted Date
- 2012-04-04
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 150
- Registration Number
- NCT00424762
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy.
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT00422955
- Locations
- 🇳🇱
GSK Investigational Site, Nijmegen, Netherlands
Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth
- Conditions
- Interventions
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2013-07-22
- Lead Sponsor
- Yale University
- Target Recruit Count
- 21
- Registration Number
- NCT00413335
- Locations
- 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
Effect of Rosiglitazone on ADMA in Critical Illness
- Conditions
- First Posted Date
- 2006-12-08
- Last Posted Date
- 2006-12-08
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 30
- Registration Number
- NCT00409097
- Locations
- 🇳🇱
VU University Medical Center, Amsterdam, Netherlands
The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy.
- Conditions
- Interventions
- First Posted Date
- 2006-11-29
- Last Posted Date
- 2010-08-24
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 13
- Registration Number
- NCT00405015
- Locations
- 🇳🇱
Clinical research Center Nijmegen, Nijmegen, Netherlands
Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease
- First Posted Date
- 2006-09-27
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 33
- Registration Number
- NCT00381238
- Locations
- 🇨🇦
GSK Investigational Site, Montreal, Quebec, Canada
RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes
- Conditions
- Interventions
- First Posted Date
- 2006-09-22
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 4447
- Registration Number
- NCT00379769
- Locations
- 🇬🇧
GSK Investigational Site, Worle, Weston-Super-Mare, United Kingdom
Metabolic Effects of Treatment in Patients With Recently Diagnosed Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2012-11-02
- Lead Sponsor
- Aristotle University Of Thessaloniki
- Target Recruit Count
- 100
- Registration Number
- NCT00373178
- Locations
- 🇬🇷
AHEPA University Hospital of Thessaloniki, Thessaloniki, Greece
🇬🇷Aristotle University of Thessaloniki, Thessaloniki, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.